df16e2f1-59a7-444d-9eab-c8d3b23b080d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- PROTEIN_SECRETION+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- TGF_BETA_SIGNALING+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- ANDROGEN_RESPONSE+0.200
- KRAS_SIGNALING_UP+0.200
- TNFA_SIGNALING_VIA_NFKB+0.200
- APOPTOSIS+0.100
- COAGULATION+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.300
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- MYC_TARGETS_V2-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- CHOLESTEROL_HOMEOSTASIS-0.200
- FATTY_ACID_METABOLISM-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-MP-A4SY-01A-21R-A24X-07 | — | cohortA1 | 0.762 |
| 2 | 4f0c3ed0-647a-422e-b771-f201f5d5d29e | — | — | 0.729 |
| 3 | TCGA-E9-A1RI-01A-11R-A169-07 | — | A | 0.693 |
| 4 | 5af21474-88f9-4885-82d2-9c84b2ded99a | — | — | 0.686 |
| 5 | TCGA-CV-7416-01A-11R-2081-07 | — | — | 0.674 |
| 6 | SRR6013569 | — | cohortMD2 | 0.666 |
| 7 | TCGA-E2-A1BC-01A-11R-A12P-07 | — | A | 0.663 |
| 8 | TCGA-66-2789-01A-01R-0980-07 | — | cohortSQ1 | 0.659 |
| 9 | SRR8518416 | — | E | 0.650 |
| 10 | TCGA-44-2665-01A-01R-A278-07 | — | cohortMD2 | 0.633 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |